Supporting oncology professionals through education
The content on this site is intended for healthcare professionals only
The content on this site is intended for healthcare professionals only
Opportunity for exploring anti-PD-L1 and anti-PD-1 agents in combination with targeted therapies
A group of Italian and Swiss researchers have found a correlation between PD-L1 expression and EGFR mutation, as well as between PD-1 expression and KRAS mutations in a cohort of molecularly selected patients with non-small-cell lung cancer (NSCLC).
To read the rest of this story visit the ESMO site.